Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease?


ERDOĞAN ORHAN İ., ŞENOL DENİZ F. S.

CURRENT PHARMACEUTICAL DESIGN, cilt.27, sa.2, ss.143-158, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 27 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2174/1381612826666200728144605
  • Dergi Adı: CURRENT PHARMACEUTICAL DESIGN
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.143-158
  • Anahtar Kelimeler: Xanthine oxidase, inhibition, gout, plant, natural sources, agrimoniin and ellagitannin, SERUM URIC-ACID, ACTIVITY IN-VITRO, XANTHINE-OXIDASE, ANTIOXIDANT ACTIVITY, ANTIINFLAMMATORY ACTIVITIES, PHENOLIC CONSTITUENTS, ENDOTHELIAL FUNCTION, ENDOPHYTIC FUNGUS, ENZYME-INHIBITORS, ALPHA-GLUCOSIDASE
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Xanthine oxidase (EC 1.17.3.2) (XO) is one of the main enzymatic sources that create reactive oxygen species (ROS) in the living system. It is a dehydrogenase enzyme that performs electron transfer to nicotinamide adenine dinucleotide (NAD(+)), while oxidizing hypoxanthin. which is an intermediate compound in purine catabolism, first to xanthine and then to uric acid. XO turns into an oxidant enzyme that oxidizes thiol groups under certain stress conditions in the tissue. The last metabolic step, in which hypoxanthin turns into uric acid, is catalyzed by XO. Uric acid, considered a waste product, can cause kidney stones and gouty-type arthritis as it is crystallized, when present in high concentrations. Thus, XO inhibitors are one of the drug classes used against gout, a purine metabolism disease that causes urate crystal storage in the joint and its surroundings caused by hyperuricemia. irate-lowering therapy includes XO inhibitors that reduce uric acid production as well as uricosuric drugs that increase urea excretion. Current drugs that obstruct uric acid synthesis through XO inhibition are allopurinol, febuxostat, and uricase. However, since the side effects, safety and tolerability problems of some current gout medications still exist, intensive research is ongoing to look for new, effective, and safer XO inhibitors of natural or synthetic origins for the treatment of the disease. In the present review, we aimed to assess in detail XO inhibitory capacities of pure natural compounds along with the extracts from plants and other natural sources via screening Pubmed, Web of Science (WoS), Scopus, and Google Academic. The data pointed out to the fact that natural products, particularly phenolics such as flavonoids (quercetin, apigenin, and scutellarein), tannins (agrimoniin and ellagitannin), chalcones (melanoxethin), triterpenes (ginsenoside Rd and ursolic acid), stilbenes (resveratrol and piceatannol), alkaloids (berberin and palmatin) have a great potential for new XO inhibitors capable of use against gout disease. In addition, not only plants but other biological sources such as microfungi, macrofungi, lichens, insects (silk worms, ants, etc) seem to be the promising sources of novel XO inhibitors.